Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  ONO PHARMACEUTICAL CO., LTD.    4528   JP3197600004

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( JPY)
Sales 2018 253 B
EBIT 2018 -
Net income 2018 37 842 M
Finance 2018 133 B
Yield 2018 1,90%
Sales 2019 272 B
EBIT 2019 -
Net income 2019 45 356 M
Finance 2019 143 B
Yield 2019 1,95%
P/E ratio 2018 33,93
P/E ratio 2019 26,62
EV / Sales2018 4,77x
EV / Sales2019 4,39x
Capitalization 1 337 B
More Financials
Company
Ono Pharmaceutical Co., Ltd. engages in the production, purchase, and sale of pharmaceutical and diagnostic reagents focusing on prescription pharmaceuticals.Its products include respiratory, digestive, urinary, chemotherapy, hormone, vitamins, and metabolic drugs.The company was founded by Ichibei... 
More about the company
Surperformance© ratings of ONO PHARMACEUTICAL CO., LT
Trading Rating : Investor Rating :
More Ratings
Latest news on ONO PHARMACEUTICAL CO., LT
11/16 ONO PHARMACEUTICAL : Encouraging Response Observed with Opdivo (nivolumab) Plus ..
11/11 ONO PHARMACEUTICAL : Neurimmune Announces Collaboration With Ono Pharmaceutical ..
11/10 ONO PHARMACEUTICAL : Opdivo Plus Yervoy Combination Delivered Overall Survival B..
11/09 ONO PHARMACEUTICAL : announces collaboration with Neurimmune in Neurodegenerativ..
11/08 ONO PHARMACEUTICAL : Opdivo (nivolumab) Demonstrates Superior Three-Year Surviva..
11/07 ONO PHARMACEUTICAL : Opdivo® (Nivolumab) Intravenous Infusion Approved in Taiwan..
10/31 ONO PHARMACEUTICAL : European Medicines Agency Validates Bristol-Myers Squibb&rs..
10/31 ONO PHARMACEUTICAL : Notice Regarding Completion of Cancellation of Treasury Sha..
10/30 ONO PHARMACEUTICAL : Opdivo® (Nivolumab) Intravenous Infusion Approved in Taiwan..
10/26 ONO PHARMACEUTICAL : Revisions of Consolidated Financial Forecasts (77.5KB)
More news
Sector news : Generic Pharmaceuticals
11/18DJADRs End Higher; JA Solar, NetEase Trade Actively
11/17 British stocks fall back as Carillion crashes, Sky soars
11/17DJROCHE : U.S. FDA Approves Roche's Gazyva for Untreated Follicular Lymphoma
11/17DJROCHE : to Acquire U.S. Software Company Viewics
11/16 Europe approves GlaxoSmithKline's new triple lung drug
More sector news : Generic Pharmaceuticals
News from SeekingAlpha
10/03 Ono Pharmaceutical Needs To Reinvest Its Windfall
09/29 YOUR DAILY PHARMA SCOOP : Axovant's Promised Upside, Gilead's Whistleblower Trou..
06/22 Only Bristol Bucks Big Pharma's Drive For External Reliance
06/02 3 THINGS IN BIOTECH YOU SHOULD LEARN : June 2, 2017
05/31 Array out-licenses binimetinib and encorafenib to Ono Pharma for Japan and So..
Chart ONO PHARMACEUTICAL CO., LT
Duration : Period :
ONO PHARMACEUTICAL CO., LT Technical Analysis Chart | 4528 | JP3197600004 | 4-Traders
Technical analysis trends ONO PHARMACEUTICAL CO., LT
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 2 790  JPY
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Gyo Sagara President & Representative Director
Shozo Matsuoka Executive Officer & Manager-Medical Affairs
Kazuhito Kawabata Director & Managing Executive Officer
Hiroshi Awata Director, EVP & General Manager-Development
Isao Ono Director & Managing Executive Officer
Sector and Competitors